All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for MERCK & CO. INC. · Manufacturer of pharmaceuticals

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Oct 16, 2025

Official filing document

Bills named in this filing 4

HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 4

Health Issues

Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity.

Medicare/Medicaid

Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 946/S. 1862, ORPHAN Cures Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to drug pricing and pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Taxation/Internal Revenue Code

H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.

Trade (domestic/foreign)

Issues related to tariffs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.